Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is reporting third quarter financial results on Monday 2nd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, JAZZ is expected to report 3Q20 income of $ 4.08 per share from revenue of $ 577.58 million.
For the full year, analysts anticipate top line of $ 2281.35 million, while looking forward to income of $ 12.47 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 2,225.00 million ~ $ 2,325.00 million, where as bottomline are predicted in a range of $ 11.90 ~ $ 13.00 per share
Click Here For More Historical Outlooks Of Jazz Pharmaceuticals plc
Previous Quarter Performance
Jazz Pharmaceuticals plc recorded income for the second quarter of $ 3.71 per share, from the revenue of $ 562.44 million. The quarterly earnings contracted 8.40 percent while revenues boosted 5.30 percent compared with the same quarter last year.
Wall street analysts are predicting, JAZZ to report 2Q20 income of $ 3.11 per share from revenue of $ 504.65 million. The bottom line results beat street analysts by $ 0.6 or 19.29 percent, at the same time, top line results outshined analysts by $ 57.79 million or 11.45 percent.
Stock Performance
On Friday, shares of Jazz Pharmaceuticals plc has traded high as $ 146.37 and has cracked $ 143.05 on the downward trend, reaching $ 144.10 with volume of 519.20 thousand shares.
According to the previous trading day, closing price of $ 144.10, representing a 67.62 % increase from the 52 week low of $ 86.88 and a 6.8 % decrease over the 52 week high of $ 156.26.
The company has a market capital of $ 7.99 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 9th October 2020, maintained by Jefferies Financial Group at Buy rating, with $ 188.00 target price.
- On 9th October 2020, maintained by HC Wainwright at Buy rating, with $ 185.00 target price.
- On 9th October 2020, maintained by SVB Leerink at Outperform rating, with $ 182.00 target price.
- On 14th September 2020, downgraded by Goldman Sachs Group to Sell from Neutral rating.
Conference Call
Jazz Pharmaceuticals plc will be hosting a conference call at 4:30 PM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.jazzpharma.com
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia.
